Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective

BACKGROUND: Ranibizumab and aflibercept are alternative anti-vascular endothelial growth factor agents approved for the treatment of visual impairment (VI) due to diabetic macular edema (DME). OBJECTIVE: To estimate, from a UK healthcare perspective, the cost-effectiveness of ranibizumab 0.5 mg pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Régnier, Stephane A, Malcolm, William, Haig, Jennifer, Xue, Weiguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427067/
https://www.ncbi.nlm.nih.gov/pubmed/25999748
http://dx.doi.org/10.2147/CEOR.S82556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427067/
https://www.ncbi.nlm.nih.gov/pubmed/25999748
http://dx.doi.org/10.2147/CEOR.S82556

Ejemplares similares